Fundraising Fox
Cloverleafbio
Founded 2023 · 4 employees on LinkedIn · 1 known investors
Find your way into Cloverleafbio
Sign up to see every warm intro you have to Cloverleafbio
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Cloverleafbio team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Cloverleaf Bio is developing engineered tRNA therapeutics for oncology, designed to inhibit multiple enzymes required for cancer growth from a single molecule. The company focuses on cancer treatment within the biotech and therapeutics space.
Founders & leadership
Cloverleafbio was founded in 2023 by Austin Draycott, Wendy Gilbert, and Cole Lewis.
AD
Austin DraycottCo-FounderAustin Draycott completed a PhD in biochemistry at Yale University under Wendy Gilbert, where he developed methods to study epitranscriptomic modifications and their role in lung cancer. He is co-founder and CEO of Cloverleaf Bio, which develops engineered tRNA therapeutics for oncology.
WG
Wendy GilbertCo-Founder
Investors · 1
Frequently asked questions
- What does Cloverleafbio do?
- Cloverleaf Bio is developing engineered tRNA therapeutics for oncology, designed to inhibit multiple enzymes required for cancer growth from a single molecule. The company focuses on cancer treatment within the biotech and therapeutics space.
- Who founded Cloverleafbio?
- Cloverleafbio was founded by Austin Draycott, Wendy Gilbert, Cole Lewis in 2023.
- Who are Cloverleafbio's investors?
- Cloverleafbio's investors include Draper Associates.